Our researchers are fighting the coronavirus pandemic with innovative approaches. With your donation you can support them in developing drugs and vaccines against the virus or in deciphering the mechanisms of disease development and progression. Here you can find out all about donation opportunities.
The coronaviruses are a family of viruses that includes a series of very different pathogens. These viruses usually infect mammals, rodents, and birds, but only few coronaviruses adapted to humans. They did this with great success: About one third of all typical "common colds" and some cases of diarrhoea as well are caused by these RNA Viruses, which are the largest of their kind. We have compiled more information about the coronaviruses for you.
With the pathogen SARS-CoV-2, a novel virus that can cause respiratory diseases and pneumonia has been spreading worldwide since the end of 2019. Here we will keep you informed about current developments in research and provide answers to the most important questions.
HomePressVideos & PodcastsVideos
Results 1 to 9 of total 48
Web Content Manager
+49 531 6181-1411
+49 531 6181-1499
This year, three of the renowned ERC Starting Grants were awarded to the Helmholtz Centre for Infection Research (HZI). These grants from the European Research Council (ERC) are specifically designed to help young scientists and researchers make the leap to independent top-level research. Across all disciplines, the ERC will award a total of 436 Starting Grants in 2020 with a total…
"Even when growing together under the same condition individual bacteria can behave very differently," says Prof Jörg Vogel, director of the HIRI and chair of the Institute for Molecular Infection Biology at the Medical Faculty of the Julius-Maximilians-Universität in Würzburg. "Some stand out from the crowd of their genetically identical siblings and defy life-threatening…
As a member of the CARE consortium, the Helmholtz Centre for Infection Research (HZI) will contribute its expertise in pharmacology of anti-infective compounds. Its Pharmacokinetics/Pharmacodynamics unit (PK/PD unit), that has been initiated by the German Center for Infection Research (DZIF), will be engaged in transitioning active compounds to drug candidates. "We are looking…
Most patients infected with the coronavirus SARS-CoV-2 show mild or even no symptoms. However, 10 to 20 percent of patients develop pneumonia during the course of COVID-19 disease, some of them with life-threatening consequences. "There is still not very much known about the causes of these severe courses of the disease. The high inflammation levels measured in those affected…
The strategies for dealing with the COVID-19 pandemic depend largely on estimation of the actual number of infected people. In addition to the cases tested and confirmed, there is an unknown number of people who have undergone infection with or without mild symptoms and have not been tested. They will no longer be at risk for at least some time, because their immune system has…